Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2006 Mar;5(3):235-46.

An APRIL to remember: novel TNF ligands as therapeutic targets.

Author information

1
Department of Autoimmunity and Inflammation, ZymoGenetics, Inc. 1201 Eastlake Avenue East, Seattle, Washington 98102, USA. dillons@zgi.com

Abstract

Since their discovery in 1998, the two TNF family members APRIL and BLyS/BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.

PMID:
16474316
DOI:
10.1038/nrd1982
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center